Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2953MR)

This product GTTS-WQ2953MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ2953MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4436MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ2387MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ6424MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ1081MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ13044MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ1773MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ1462MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ13125MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04360365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW